Saturday, 31 October 2026European Markets

ORPEA Stock Skyrockets 33% In Recent Trading Sessions: What's Driving The Growth?

Loading stream...

(vianews) - orpea (orp.pa), listed on the cac 40 index, experienced an extraordinary surge in its share price over the last 10 sessions - rising 33.33% from eur0.02 to eur0.02 as of 15:24 est friday afternoon following two consecutive losses. orpea's cac 40 index component, orpea is currently down by 1.17% to eur7,363.70 after experiencing a steady downward trend over recent days. orpea closed at an all-time low price of eur0.02, over 99.991% lower than its 52-week high of eur8.93.

about orpea

orpea sa is a leading european healthcare provider, specializing in nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals as well as psychiatric hospitals. our company provides personalized support services, accommodation and meals, daily events, entertainment and therapeutic workshops, catering to an array of conditions including geriatrics, musculoskeletal issues, nervous system conditions, cardiovascular issues, hematology and oncology. orpea sa offers home care services, such as housekeeping, daily life assistance and mobility assistance services. orpea sa operates across 23 countries across europe, latin america, and asia and serves a range of patients such as geriatric, children, young adults, parent-child relationships, public/private patients. established in 1989 and headquartered in puteaux in france.

yearly analysis

orpea's stock is currently trading at eur0.02, significantly less than its 52-week high of eur8.93 but higher than its 52-week low of eur0.01. orpea expects its sales growth for this year at 8.3% and 7.8% for next year.

technical analysis

orpea stock has experienced a downward trend recently, falling significantly below both its 50-day and 200-day moving averages. this indicates a potential shift in momentum for orpea's stock, prompting investors to closely watch its future performance. furthermore, orpea's volume is currently lower than usual, which may also impact price fluctuations. orpea's intraday variation average has been negative over the past week, positive over the last month, and positive over the last quarter. this could indicate potential shifts in its price action; however, past performance does not guarantee future outcomes. stochastic oscillator analysis indicates that orpea stock may currently be considered overbought, suggesting an imminent reversal or consolidation event may take place. orpea stock is currently experiencing a difficult period and investors should use caution in their investments by closely following company news and performance indicators to make informed investment decisions.

quarter analysis

revenue growthincreasing year-on-year quarterly revenue growth was at 10.7%, amounting to 4.93b for the last twelve months.

equity analysis

according to information available, orpea's trailing 12-month earnings per share (eps) stands at eur-4.11 - which indicates a negative earnings per share and indicates the company may not be producing enough profits to sustain operations and return value back to shareholders. return on equity for the trailing twelve month is negative at -445.48% indicating that for every eur1 invested by shareholders, the company cannot produce a return in profit. overall, orpea may be experiencing difficulties in terms of profitability and returns for its shareholders. investors should carefully consider these aspects along with any relevant data before making investment decisions.

more news about orpea (orp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com